Welcome! You are invited to join a webinar: Post-ASCO 2025 Lung Cancer Highlights. After registering, you will receive a confirmation email about joining the webinar.

Virtual webinar featuring presentations & discussions on selected abstracts in lung cancer from ASCO 2025. Chaired by Noemí Reguart Moderated by Stephen Liu, Nicolas Girard 25 June | 15:30–17:30 CEST/ 08:30–10:30 CDT/ 14:30–16:30 BST Agenda available soon

Read the full article here

Related Articles

ORCHARD: Osimertinib Plus Necitumumab in Patients With Epidermal Growth Factor Receptor–Mutated Advanced Non–Small Cell Lung Cancer With a Secondary Epidermal Growth Factor Receptor Alteration Whose Disease Had Progressed on First-Line Osimertinib | JCO Precision Oncology

PURPOSEORCHARD (ClinicalTrials.gov identifier: NCT03944772) is a phase II, biomarker-directed platform study designed to characterize resistance mechanisms and evaluate novel drug combinations in patients with epidermal…